Lv71
3260 积分 2022-12-18 加入
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
1个月前
已完结
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
1个月前
已完结
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
1个月前
已完结
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer
1个月前
已完结
Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?
1个月前
已完结
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data
1个月前
已完结
First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA
1个月前
已关闭
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
2个月前
已完结
Cancer immunotherapy using checkpoint blockade
2个月前
已完结
皖公网安备34019202002308
